Printer Friendly

ROBERTS PHARMACEUTICAL CORPORATION ELECTS TWO NEW DIRECTORS

 EATONTOWN, N.J., Nov. 10 /PRNewswire/ -- Roberts Pharmaceutical Corporation (NASDAQ-NMS: RPCX) announced today the election of Robert W. Loy, Roberts Chief Operating Officer and Akihiko Matsubara, Yamanouchi Pharmaceutical Co., Ltd. of Japan to Roberts Board of Directors; thereby filling two recent vacancies from its previous Board. The election of Mr. Loy fills a vacancy created by the recent death of A. James Sederis, a long standing member of the Roberts Board. The election of Mr. Matsubara fills a vacancy created by the recent resignation of Dr. Toichi Takenaka of Yamanouchi. Dr. Takenaka, who had served on the Roberts Board for almost two years, resigned from the Roberts Board due to a significant increase in responsibilities primarily resulting from the appointment of Dr. Takenaka to the Yamanouchi Board of Directors. Membership of the Board remains at nine board members.
 Mr. Loy has 30 years of increasing responsibility in the pharmaceutical industry and has held the title of Chief Operating Officer at Roberts for over a year. Prior to joining Roberts, he was Vice President, International Sales and Marketing with Hollister, Inc., and prior to that held various senior level positions throughout the Squibb Corporation, most notably Vice President, Worldwide Operations for the Squibb Derm Division. Mr. Loy received his Bachelor's degree from Old Dominion University.
 Mr. Matsubara currently serves as a senior member of the Corporate Planning Department of Yamanouchi Pharmaceutical Co., Ltd. of Japan. He has held this position since 1988 and he has been employed by Yamanouchi for over 15 years. From 1981 to 1988, Mr. Matsubara has held various management positions at Yamanouchi. Mr. Matsubara is a graduate of Hitotsubashi University of Japan.
 Dr. Robert A. Vukovich, Roberts CEO and Chairman, stated that, "We are pleased to elect two such distinguished and qualified members to serve on the Board of Directors of Roberts. Although the contributions of the late A. James Sederis and Dr. Takenaka will surely be missed, we view Mr. Loy's and Mr. Matsubara's membership on the Board as being a significant asset and look forward to their providing input and guidance concerning the overall continued growth of the Company."
 Roberts Pharmaceutical Corporation is an international pharmaceutical company focusing on the acquisition and development of late-stage development products and the acquisition of currently marketed prescription and nonprescription products. Roberts currently markets its products in seven countries and has operating subsidiaries in the United States, Canada and the United Kingdom. Roberts has six prescription pharmaceutical products in late-stage clinical development and currently markets products primarily in six major therapeutic areas: Cardiovascular, Respiratory, Gynecology/Endocrinology, Urology, Oncology and Gastroenterology.
 -0- 11/10/93
 /CONTACT: Anthony Maris of Roberts Pharmaceutical, 908-389-1182/
 (RPCX)


CO: Roberts Pharmaceutical Corporation ST: New Jersey IN: MTC SU: PER

MP -- NY086 -- 2865 11/10/93 15:16 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 10, 1993
Words:463
Previous Article:WHAT TO TAKE ON THE MODERN-DAY MAYFLOWER? TODAY'S PILGRIMS WOULD PACK CLOTHES, TELEVISIONS, CARS AND FOOD FOR JOURNEY TO NEW LAND
Next Article:WALLACE COMPUTER SERVICES ELECTS DIRECTORS
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters